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Objective: Despite recent recognition that
the epithelial-mesenchymal transition
(EMT) program acts in a dynamic manner
(termed Epithelial to Mesenchymal Plastic-
ity or EMP) during carcinoma metastasis,
it has largely been ignored in the discovery
and development of EMT-targeted thera-
pies. In part, this has stemmed from a lack
of preclinical models that can mimic the
full dynamic nature of EMP and the per-
ception that the EMT-reverting transition
[or mesenchymal-epithelial reverting tran-
sition; (MErT)] is a mere antithesis of
EMT. The objective of this study was to
develop the first PCa model capable of
recapitulating the dynamic nature of EMP.
Methods: The LNCaP cell line was uti-
lised to develop a reversible model of
SNAI1-mediated EMT. Transcriptional
profiling and an array of biological assays
were performed to assess the role of EMT
and MErT on phenotypes relevant to can-
cer progression.
Results: Temporal transcriptional profil-
ing of EMT-induced tumour cells during
their active reversion to an epithelial phe-
notype, revealed MErT to be enriched in
clinical samples of lethal metastatic castra-
tion resistant prostate cancer. A MErT
signature was identified to correlate with
faster prostate cancer patient relapse and
poor survival across multiple carcinoma
types. MErT is not simply the mirror
image of EMT and reveal unique tran-
scriptional subprograms operating during
MErT.
Conclusions: In this study we have identi-
fied a MErT associated with carcinoma
metastasis and poor clinical outcome, and
reveal unique transcriptional networks
activated during the reversion of EMT.
This study highlights the need to consider
the dynamic nature of EMP during the
metastatic process for the application of
potential EMT-targeted therapies into the
clinic, as inhibiting EMT (i.e. activating
MErT) may reawaken dormant dissemi-
nated cells and be detrimental to the
patient.
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Objective: Prostate cancer is the leading
cause of cancer-related deaths among
men, in particular, the fourth most
common cause of death from cancer
among Asian/Pacific men. Tumor micro-
environment contributes to the origin,
restriction, invasion and progression of
prostate cancer. Oncogenic insults induced
by gene mutation may promote or restrict
tumor progression depending on activa-
tion of cellular senescence such as Pten
loss induced p53-dependent tumor restric-
tion. ARF plays an important role in
senescence but its function in genetic con-
text of Pten loss is largely unknown. p53
mutation is frequently found in various
cancers and PTEN mutation or inactiva-
tion is found in 90% cases of prostate can-
cer. Genetic engineering mouse model
with Pten loss would allow us to explore
novel signaling and avenues for targeted
therapy.
Methods: Pten/Trp53 knockout mouse
model, cell line culture, immunofluores-
cence, immunohistochemistry were applied
for investigation.
Results: ARF expression is found in both
epithelial and stromal cells in prostate can-
cer of Pten/Trp53 null mice. ARF overex-
pression decreased cellular adhesion
through targeting extracellular matrix via
matrix metalloproteinase (MMP)7 in
human prostate cancer PC3 cells. ARF
associates with MMP7 in PC3 and DU145
cells. MMP7 expression was positively
correlated with ARF elevation in human
prostate cancer specimens.
Conclusions: Oncogenic insults may cause
damages to cellular matrix and regulate
cancer progression through changes in
microenvironment. Combined targeting of
ARF with MMP7 inhibitor would be a
novel avenue for treatment of aggressive
prostate cancer.
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Purpose: Androgen receptor splice vari-
ants (ARvs) are upregulated in response to
castration, and can activate transcription
in the absence of ligand. Recent evidence
suggests that ARv7 expression predicts
resistance to abiraterone and enzalutamide.
We were therefore interested to determine
the expression of ARv7 in localized pros-
tate cancer, and correlate this with
response to an abiraterone-containing cas-
tration regimen.
Patients and Methods: We performed an
open label Phase II neoadjuvant study of
degarelix, abiraterone, bicalutamide and
prednisolone for 24 weeks in men with
high-risk clinically localized prostate can-
cer using an optimal 2-stage design. The
primary endpoints were safety/tolerability
and pT0 response rate. ARv7 expression
was determined by immunohistochemistry
and qRT-PCR in both pre- and post
treatment tumor specimens, and correlated
with pathological response.
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